|
|
|||
|
|||
|
|
|||
|
allergies of dogs |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
allergies of dogs DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide allergies of dogs. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water allergies of dogs. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone allergies of dogs. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration allergies of dogs. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide allergies of dogs.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans allergies of dogs. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs allergies of dogs. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness allergies of dogs. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges allergies of dogs. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma allergies of dogs. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma allergies of dogs. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge allergies of dogs. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma allergies of dogs. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma allergies of dogs. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg allergies of dogs. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data allergies of dogs. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% allergies of dogs. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below allergies of dogs. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed allergies of dogs. Elderly: The apparent oral clearance of zafirlukast decreases with age allergies of dogs. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients allergies of dogs. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults allergies of dogs. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects allergies of dogs. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects allergies of dogs. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| aallergies of dogs alllergies of dogs alllergies of dogs alleergies of dogs allerrgies of dogs allerggies of dogs allergiies of dogs allergiees of dogs allergiess of dogs allergies of dogs allergies oof dogs allergies off dogs allergies of dogs allergies of ddogs allergies of doogs allergies of doggs allergies of dogss llergies of dogs alergies of dogs alergies of dogs allrgies of dogs allegies of dogs alleries of dogs allerges of dogs allergis of dogs allergie of dogs allergiesof dogs allergies f dogs allergies o dogs allergies ofdogs allergies of ogs allergies of dgs allergies of dos allergies of dog a llergies of dogs al lergies of dogs all ergies of dogs alle rgies of dogs aller gies of dogs allerg ies of dogs allergi es of dogs allergie s of dogs allergies of dogs allergies of dogs allergies o f dogs allergies of dogs allergies of dogs allergies of d ogs allergies of do gs allergies of dog s allergies of dogs lalergies of dogs allergies of dogs alelrgies of dogs allregies of dogs allegries of dogs alleriges of dogs allergeis of dogs allergise of dogs allergie sof dogs allergieso f dogs allergies fo dogs allergies o fdogs allergies ofd ogs allergies of odgs allergies of dgos allergies of dosg aallergies of dogs theallergies of dogs allergies of dogs | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
